Gimsilumab - Eisai Inc/Roivant Sciences
Alternative Names: KIN-1901; MORAb 022Latest Information Update: 28 Dec 2022
At a glance
- Originator Morphotek
- Developer Eisai Inc; Kinevant Sciences GmbH; Ludwig Institute for Cancer Research; Morphotek; Roivant Sciences
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ankylosing spondylitis; SARS-CoV-2 acute respiratory disease
- Discontinued Cancer; Rheumatoid arthritis
Most Recent Events
- 28 Dec 2022 No development reported - Phase-II for SARS-COV-2 acute respiratory disease in USA (IV)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Ankylosing-spondylitis in Canada (SC, Injection)
- 13 Dec 2021 Efficacy data from the phase II BREATHE trial presented at the American Heart Association Scientific Sessions 2021 (AHA-2021)